The SBUs to be operational from December this year, would have a field force of around 150 representatives.
Commenting on the companys plans, JB Chemicals & Pharmaceuticals chairman and managing director JB Mody in a release said, "Our vision is to create a strong base in niche segments in neuro-psychiatry and oncology segments for a sustainable long term competitive advantage."
Currently CNS segment (neuro-psychiatry) is growing at 15 per cent per annum with a market size of Rs 600 crore as per AC Nielsen ORG MARG, while oncology is growing at 40 per cent with a market size of Rs 200 crore.
The neuro-psychiatry and speciality products division will be christened Zephyr. The division will also have products focussing on gastroenterology and urology segments.
The company also plans to create a franchisee division, christened Uniquest. JB Chemicals will manufacture and supply the products and promotional inputs to franchisees to promote and market the products through their field force, a JB Chemicals release said. The entire operations will be controlled by the company through one national head of marketing based in Mumbai.
The company has 11 state-of-the-art manufacturing facilities at four locations in India and has reported a net profit of Rs 19.1 crore on a turnover of Rs 96.06 crore for the second quarter ended September 30, 2003.